title: Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy.
abstract: HB-EGF, a member of the EGF family of growth factors, exerts its biological activity through activation of the EGFR and other ErbB receptors. HB-EGF participates in diverse biological processes, including heart development and maintenance, skin wound healing, eyelid formation, blastocyst implantation, progression of atherosclerosis and tumor formation, through the activation of signaling molecules downstream of ErbB receptors and interactions with molecules associated with HB-EGF. Recent studies have indicated that HB-EGF gene expression is significantly elevated in many human cancers and its expression level in a number of cancer-derived cell lines is much higher than those of other EGFR ligands. Several lines of evidence have indicated that HB-EGF plays a key role in the acquisition of malignant phenotypes, such as tumorigenicity, invasion, metastasis and resistance to chemotherapy. Studies in vitro and in vivo have indicated that HB-EGF expression is essential for tumor formation of cancer-derived cell lines. CRM197, a specific inhibitor of HB-EGF, and an antibody against HB-EGF are both able to inhibit tumor growth in nude mice. These results indicate that HB-EGF is a promising target for cancer therapy, and that the development of targeting tools against HB-EGF could represent a novel type of therapeutic strategy, as an alternative to targeting ErbB receptors.
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Fukuoka University, 45-1, 7-Chome Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
authors.forename: Shingo
authors.initials: S
authors.lastname: Miyamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yagi
authors.forename: Fusanori
authors.initials: F
authors.lastname: Yotsumoto
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Kawarabayashi
authors.forename: Eisuke
authors.initials: E
authors.lastname: Mekada
mesh_terms: D000818:Animals; D002465:Cell Movement; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D005260:Female; D018815:Genes, erbB; D066257:Heparin-binding EGF-like Growth Factor; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000628:therapy; D010641:Phenotype; D015533:Transcriptional Activation
chemical_list: C587883:HBEGF protein, human; C587884:Hbegf protein, mouse; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; D004815:Epidermal Growth Factor